FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1993218744> ?p ?o ?g. }

• W1993218744 abstract "Objective: To report long-term outcomes and safety of fingolimod in relapsing multiple sclerosis (RMS) patients participating in a phase 2 study. Background After the 6-month (M) placebo controlled study in which fingolimod (1.25mg and 5mg dose groups) significantly reduced MRI and relapse activity compared to placebo all patients were invited to continue on fingolimod. The final analysis after 7 years is presented. Design/Methods: In the extension, placebo patients were re-randomized to fingolimod 1.25mg or 5mg (placebo/fingolimod group); fingolimod patients (1.25 or 5mg) continued with their core phase dose (fingolimod group). After the M24 visit, all patients received open-label, 1.25mg fingolimod and between M24-M60 were converted to 0.5mg. Results: Of 281 initially randomized patients 122 (43.4%) completed up to 7 years on study (core and extension). The overall ARR for the fingolimod group was 0.16 and for placebo/fingolimod 0.21. By study completion, 55-66% of fingolimod and 44% of placebo/fingolimod patients were relapse-free. The KM estimate of the proportion of patients who were free from 6-month confirmed disability progression ranged from 53-70% for both groups. At the end of study, 83% of all remaining patients were free of gadolinium-enhanced lesions. No increase in T2 lesion volume was observed. No chronic effects of fingolimod treatment were observed on heart rate or atrioventricular conduction. No cases of confirmed macular edema were observed. Twelve cases of skin malignancies have been reported (majority within the first 3 years): 5, basal cell carcinoma; 4, squamous cell carcinoma; 3, malignant melanoma. Conclusions: Long-term (>7 years) fingolimod treatment was associated with sustained low MRI and clinical disease activity in those remaining on therapy and was well tolerated with no new safety concerns arising with long-term dosing. Supported by: Novartis Pharma AG, Basel, Switzerland. Disclosure: Dr. Antel has received personal compensation for activities with Sanofi-Aventis Pharmaceuticals, Inc., Biogen Idec, Novartis, Serono, Inc., Genzyme Corporation, Teva Neuroscience, and GlaxoSmithKline. Dr. Antel has received personal compensation in an editorial capacity for Multiple Sclerosis. Dr. Antel has received research support from Novartis. Dr. Montalban has received personal compensation for activities with Bayer Schering Pharma, Biogen Idec, EMD Merck Serono, Genentech, Genzyme, Novartis, sanofi-aventis, Teva Pharmaceuticals, Almirall and BTG. Dr. Montalban has received research support from Bayer Schering Pharma, Biogen Idec, EMD Merck Serono, Genentech, Genzyme, Novartis, sanofi-aventis, Teva Pharmaceuticals, Almirall and BTG. Dr. O9Connor has received personal compensation for activities with Abbott Labratories, Inc., Bayer Pharmaceuticals Corporation, Biogen Idec, BioMS, Cognosci, Daiichi Pharmaceuticals Corporation, Serono, Inc., Genentech, Inc., Genmab, Novartis, Roche Diagnostics Corporation, Sanofi-Aventis Pharmaceuticals, Inc., Teva Neuroscience, Warburg Pincus and Wyeth Pharmaceuticals as a consultant. Dr. O9Connor has received research support from Abbott Labratories, Bayer Pharmaceuticals Corporation, Biogen Idec, BioMS, Cognosci, Daiichi Pharmaceutical Corporation, Serono, Inc., Genentech, Inc., Genmab, Novartis, Roche Diagnostics Corporation, Sanofi-Aventis Pharmaceuticals, Teva Neuroscience, Warburg Pincus and Wyeth Pharmaceuticals. Dr. De Vera has received personal compensation for activities with Novartis Pharma AG as an employee. Dr. Cremer has received personal compensation for activities with Novartis. Dr. Sfikas has received personal compensation for activities with Novartis as an employee. Dr. Comi has received personal compensation for activities with Novartis, Teva Neuroscience, Sanofi-Aventis Pharmaceuticals, Inc., Merck Serono, Bayer Schering, and Biogen Dompe. Dr. Kappos has received research support from Acorda Therapeutics, Actelion, Allozyne, BaroFold, Inc., Bayer Pharmaceuticals Corporation, Bayhill Therapeutics, Biogen Idec, Boehringer Ingelheim Pharmaceuticals, Inc, Elan Corporation, Genmab, GlaxoSmithKline, Inc., Glenmark Pharma, Merck Serono, MediciNova, Novartis, Sanofi-Aventis Pharmaceuticals, Santhera Pharmaceuticals, Shire, Roche Diagnostics, Teva Neuroscience, UCB Pharma, Pfizer Inc, Swiss MS Society, Swiss National Research Foundation, European Union, Gianni Rubatto Foundation, Novartis and Roche Research Foundations." @default.
• W1993218744 created "2016-06-24" @default.
• W1993218744 creator A5004974593 @default.
• W1993218744 creator A5015251684 @default.
• W1993218744 creator A5031171090 @default.
• W1993218744 creator A5043499649 @default.
• W1993218744 creator A5059990868 @default.
• W1993218744 creator A5066557279 @default.
• W1993218744 creator A5073654164 @default.
• W1993218744 creator A5074910128 @default.
• W1993218744 date "2012-04-22" @default.
• W1993218744 modified "2023-09-23" @default.
• W1993218744 title "Long-Term (7-Year) Data from a Phase 2 Extension Study of Fingolimod in Relapsing Multiple Sclerosis (P01.129)" @default.
• W1993218744 doi "https://doi.org/10.1212/wnl.78.1_meetingabstracts.p01.129" @default.
• W1993218744 hasPublicationYear "2012" @default.
• W1993218744 type Work @default.
• W1993218744 sameAs 1993218744 @default.
• W1993218744 citedByCount "7" @default.
• W1993218744 countsByYear W19932187442012 @default.
• W1993218744 countsByYear W19932187442013 @default.
• W1993218744 countsByYear W19932187442014 @default.
• W1993218744 countsByYear W19932187442015 @default.
• W1993218744 countsByYear W19932187442016 @default.
• W1993218744 crossrefType "journal-article" @default.
• W1993218744 hasAuthorship W1993218744A5004974593 @default.
• W1993218744 hasAuthorship W1993218744A5015251684 @default.
• W1993218744 hasAuthorship W1993218744A5031171090 @default.
• W1993218744 hasAuthorship W1993218744A5043499649 @default.
• W1993218744 hasAuthorship W1993218744A5059990868 @default.
• W1993218744 hasAuthorship W1993218744A5066557279 @default.
• W1993218744 hasAuthorship W1993218744A5073654164 @default.
• W1993218744 hasAuthorship W1993218744A5074910128 @default.
• W1993218744 hasConcept C126322002 @default.
• W1993218744 hasConcept C142724271 @default.
• W1993218744 hasConcept C203014093 @default.
• W1993218744 hasConcept C204787440 @default.
• W1993218744 hasConcept C27081682 @default.
• W1993218744 hasConcept C2776036978 @default.
• W1993218744 hasConcept C2780640218 @default.
• W1993218744 hasConcept C71924100 @default.
• W1993218744 hasConceptScore W1993218744C126322002 @default.
• W1993218744 hasConceptScore W1993218744C142724271 @default.
• W1993218744 hasConceptScore W1993218744C203014093 @default.
• W1993218744 hasConceptScore W1993218744C204787440 @default.
• W1993218744 hasConceptScore W1993218744C27081682 @default.
• W1993218744 hasConceptScore W1993218744C2776036978 @default.
• W1993218744 hasConceptScore W1993218744C2780640218 @default.
• W1993218744 hasConceptScore W1993218744C71924100 @default.
• W1993218744 hasLocation W19932187441 @default.
• W1993218744 hasOpenAccess W1993218744 @default.
• W1993218744 hasPrimaryLocation W19932187441 @default.
• W1993218744 hasRelatedWork W1716428631 @default.
• W1993218744 hasRelatedWork W2000175930 @default.
• W1993218744 hasRelatedWork W2010857151 @default.
• W1993218744 hasRelatedWork W2018827564 @default.
• W1993218744 hasRelatedWork W2059137425 @default.
• W1993218744 hasRelatedWork W2321928974 @default.
• W1993218744 hasRelatedWork W2495115483 @default.
• W1993218744 hasRelatedWork W2526294262 @default.
• W1993218744 hasRelatedWork W2801522132 @default.
• W1993218744 hasRelatedWork W2801606837 @default.
• W1993218744 hasRelatedWork W2894261635 @default.
• W1993218744 hasRelatedWork W2897679516 @default.
• W1993218744 hasRelatedWork W2898603585 @default.
• W1993218744 hasRelatedWork W2904345445 @default.
• W1993218744 hasRelatedWork W2977148743 @default.
• W1993218744 hasRelatedWork W3015049303 @default.
• W1993218744 hasRelatedWork W3111847630 @default.
• W1993218744 hasRelatedWork W3205542257 @default.
• W1993218744 hasRelatedWork W2276451602 @default.
• W1993218744 hasRelatedWork W50629113 @default.
• W1993218744 isParatext "false" @default.
• W1993218744 isRetracted "false" @default.
• W1993218744 magId "1993218744" @default.
• W1993218744 workType "article" @default.